Latest Tax Refunds News

Page 2 of 23
Legacy Minerals has lifted its Mt Carrington resource by 39% to 47.9 million tonnes, giving it scope to test a larger processing operation. The opportunity arrives alongside a tighter funding picture, with $3.5 million in cash and estimated funding of 1.75 quarters at current outgoings.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Decidr AI Industries reported a sharp quarterly fall in its invoicing-based AER, even as customer receipts reached a record and Sugarwork’s qualified pipeline expanded. The company is relying on A$11 million of annualised cost reductions and upcoming product launches to extend its runway and convert enterprise interest into recurring revenue.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Swift TV expanded its contracted footprint and qualified pipeline in the September quarter, but ended with $1.047 million in cash and only 0.9 quarters of funding at the reported burn rate. The company is relying on customer receipts, an expected $1.5 million R&D incentive and lending arrangements as commercial deployments accelerate.
Sophie Babbage
Sophie Babbage
30 Oct 2026
West Cobar Metals is preparing its first dedicated scandium drilling campaign at Salazar, with the programme expanded to include the Benriach prospect. But the company ended September with A$918,000 cash and an estimated 1.72 quarters of funding at the quarter’s reported expenditure rate.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Knosys has moved its Libero library platform into active US commercialisation, identifying near-term sales opportunities while preparing for its first customer engagements. The push comes as ARR slips to A$8.7 million and a timing-affected quarter leaves the company with 2.03 quarters of estimated funding.
Victor Sage
Victor Sage
29 Oct 2026
Resources & Energy Group has signed the definitive Maranoa mining agreement under which Rembrandt Mining will fund all development, processing and rehabilitation capital. The quarter also delivered high-grade drilling results across East Menzies, although REZ produced no gold and cash fell to A$734,000.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Marquee Resources advanced gold, lithium and antimony exploration during the September quarter, but ended with A$941,468 in cash and an estimated 1.85 quarters of funding. Yindi drilling stopped early in difficult ground, while West Spargoville produced encouraging surface results that now require follow-up work.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Janus Electric ended September with A$3.0 million in cash after a A$5.9 million operating outflow, but has since added A$11 million in CBA facilities and expanded its North American order book to 124 trucks. The next test is whether those funding arrangements convert a sizeable gross order book into customer receipts during Q2 FY2027.
Victor Sage
Victor Sage
29 Oct 2026
Control Bionics has begun converting its expanded product and regulatory pipeline into revenue, while a completed $9.75 million capital raising gives the company a larger cash buffer. The next test is whether partner-led sales and NeuroStrip trial conversions can reduce its cash burn as planned.
Victor Sage
Victor Sage
29 Oct 2026
Skin Elements has converted its New Zealand Farmlands agreement into a first NZ$150,000 ECO-Nurture delivery, while A$900,000 in placement proceeds lifted quarter-end cash to A$1.455 million. The commercial progress comes alongside a cost review and a regulatory hurdle still standing between the company and broader national sales.
Ada Torres
Ada Torres
29 Oct 2026
Zimi has moved its next-generation Matter smart-home range closer to certification and production, while securing access to more than 10,000 retail outlets through Directed. But the company ended September with $344,000 in cash after burning $714,000 on operations, leaving further funding firmly in the frame.
Sophie Babbage
Sophie Babbage
28 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026

Browse the archive

Full archive